Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the ...

Move comes 2 years after controversial exit of brand-name product ...

Key market opportunities in the inhaler solution market include the rising demand driven by increased respiratory disorders like asthma and COPD, expanding access to medicines in low and middle-income ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

Bespak is increasing pressurized metered dose inhaler manufacturing capacity to support Chiesi Group’s Carbon Minimal Inhaler (CMI) program.

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Research by broker UBS shows the S&P/ASX200 tends to rise after major geopolitical conflicts, by an average 15% one year ...

Key opportunities in the targeted drug delivery market include advances in precision medicine, next-gen carrier tech, strategic partnerships, resilient supply chains, and patient-centric design.

AptarGroup, Inc. (ATR) 47th Annual Raymond James Institutional Investor Conference March 3, 2026 1:05 PM ESTCompany ParticipantsVanessa Kanu - Executive ...

Although plastic particles in the air are increasingly coming into focus, knowledge about their distribution and effects is still limited. Chemical analyses from Leipzig now provide details from ...

Composition, interactions and resulting inhalation risk of micro- and nano-plastics in urban air. Commun Earth Environ 6, 985 (2025). DOI: 10.1038/s43247-025-02980-0 This research was funded by the ...